- Trial phase
- Approved
- Time to market
- Approved and launching October 2026 (US); EU marketing authorization application under EMA review. Label expansion for ages 6-12 targeted via sNDA in H1 2027.
- Why 4/10
- ATEBRIOZ was FDA-approved on September 25, 2026 for patients aged 12+ with FOP; there is no pending regulatory binary in the next ~12 months. The next catalyst is the sNDA submission for ages 6-12 planned for H1 2027 (more than 6 months away). As an already-approved drug launching commercially, with no imminent make-or-break decision, the impactScore is a default 4, ATEBRIOZ is one of several assets in Mirum's pipeline and Livmarli remains the dominant revenue driver.
The next catalyst is the sNDA submission planned for H1 2027 to expand ATEBRIOZ's label to children aged 6 to <12 years, building on the positive Cohort 2 data announced today. The commercial launch in October 2026 and first quarterly sales disclosure (likely on the Q3 2026 earnings call, Nov 17, 2026) will be the earliest tangible read on adoption. Watch for FDA acceptance of the sNDA and any Priority Review designation, as well as enrollment progress in Cohort 3 (ages 2 to <12).
Price Chart
Executive Summary
ATEBRIOZ (zilurgisertib, also known as INCB000928) is an oral ALK2 inhibitor approved by the FDA on September 25, 2026 for fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. Developed by Incyte and licensed to Mirum Pharmaceuticals in April 2026, it is the third approved FOP drug after Ipsen's Sohonos (2023) and Regeneron's Pasatru (August 2026). On October 26, 2026, Mirum announced positive PROGRESS Cohort 2 results showing zilurgisertib significantly reduced heterotopic ossification volume in children aged 6-12, supporting an sNDA in H1 2027. ATEBRIOZ is commercializing now (launch expected Oct 2026), but with an ultra-small patient population (~800-1,000 US patients) and two competitors already on the market, it represents a meaningful but not company-defining opportunity within Mirum's broader rare-disease portfolio, which is dominated by Livmarli ($129M Q2 2026 revenue).
How It Works
ATEBRIOZ is a once-daily pill that inhibits the ALK2 receptor, a protein that is overactive in people with FOP (fibrodysplasia ossificans progressiva, also known as 'stone man disease'). In FOP, the body's natural repair system mistakenly turns muscles, tendons, and ligaments into bone. By blocking ALK2, ATEBRIOZ interrupts this abnormal bone-forming pathway at its source, reducing the growth of new unwanted bone outside the skeleton.
Trial Status
FDA approved September 25, 2026 based on PROGRESS Cohort 1 (Phase 2, ages 12+). Cohort 2 (Phase 3, ages 6-12) met primary endpoint with topline positive results announced Oct 26, 2026; sNDA submission planned H1 2027. Cohort 3 (ages 2 to <12) is currently enrolling.
The Two-Sided Case
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Mirum Pharmaceuticals, Inc. 8-K MIRM ·Originating report